Literature DB >> 26433216

Prevalence, Employment Rate, and Cost of Schizophrenia in a High-Income Welfare Society: A Population-Based Study Using Comprehensive Health and Welfare Registers.

Stig Evensen1, Torbjørn Wisløff2, June Ullevoldsæter Lystad3, Helen Bull3, Torill Ueland4, Erik Falkum5.   

Abstract

Schizophrenia is associated with recurrent hospitalizations, need for long-term community support, poor social functioning, and low employment rates. Despite the wide- ranging financial and social burdens associated with the illness, there is great uncertainty regarding prevalence, employment rates, and the societal costs of schizophrenia. The current study investigates 12-month prevalence of patients treated for schizophrenia, employment rates, and cost of schizophrenia using a population-based top-down approach. Data were obtained from comprehensive and mandatory health and welfare registers in Norway. We identified a 12-month prevalence of 0.17% for the entire population. The employment rate among working-age individuals was 10.24%. The societal costs for the 12-month period were USD 890 million. The average cost per individual with schizophrenia was USD 106 thousand. Inpatient care and lost productivity due to high unemployment represented 33% and 29%, respectively, of the total costs. The use of mandatory health and welfare registers enabled a unique and informative analysis on true population-based datasets.
© The Author 2015. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cost-of-illness; employment; prevalence; schizophrenia

Mesh:

Year:  2015        PMID: 26433216      PMCID: PMC4753607          DOI: 10.1093/schbul/sbv141

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  29 in total

Review 1.  Schizophrenia and urbanicity: a major environmental influence--conditional on genetic risk.

Authors:  Lydia Krabbendam; Jim van Os
Journal:  Schizophr Bull       Date:  2005-09-08       Impact factor: 9.306

Review 2.  Perspectives: an international review of the national cost estimates of mental illness, 1990-2003.

Authors:  Teh-wei Hu
Journal:  J Ment Health Policy Econ       Date:  2006-03

3.  Supported employment: cost-effectiveness across six European sites.

Authors:  Martin Knapp; Anita Patel; Claire Curran; Eric Latimer; Jocelyn Catty; Thomas Becker; Robert E Drake; Angelo Fioritti; Reinhold Kilian; Christoph Lauber; Wulf Rössler; Toma Tomov; Jooske van Busschbach; Adelina Comas-Herrera; Sarah White; Durk Wiersma; Tom Burns
Journal:  World Psychiatry       Date:  2013-02       Impact factor: 49.548

Review 4.  Substance misuse in patients with schizophrenia: epidemiology and management.

Authors:  David J Kavanagh; John McGrath; John B Saunders; Glenys Dore; Dianne Clark
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  The economic cost of multiple sclerosis in Sweden in 1994.

Authors:  F Henriksson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

Review 6.  Schizophrenia and migration: a meta-analysis and review.

Authors:  Elizabeth Cantor-Graae; Jean-Paul Selten
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

7.  The global costs of schizophrenia.

Authors:  Martin Knapp; Roshni Mangalore; Judit Simon
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

Review 8.  Mental health quality and outcome measurement and improvement in Norway.

Authors:  Torleif Ruud
Journal:  Curr Opin Psychiatry       Date:  2009-11       Impact factor: 4.741

9.  Cost of schizophrenia in England.

Authors:  Roshni Mangalore; Martin Knapp
Journal:  J Ment Health Policy Econ       Date:  2007-03

10.  Diagnosing comorbidity in psychiatric hospital: challenging the validity of administrative registers.

Authors:  Terje Oiesvold; Mary Nivison; Vidje Hansen; Ingunn Skre; Line Ostensen; Knut W Sørgaard
Journal:  BMC Psychiatry       Date:  2013-01-08       Impact factor: 3.630

View more
  31 in total

1.  Costs and outcomes for individuals with psychosis prior to hospital admission and following discharge in Bulgaria.

Authors:  Desislava Ignatova; Maria Kamusheva; Guenka Petrova; Georgi Onchev
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-03-30       Impact factor: 4.328

Review 2.  Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.

Authors:  Colm M P O'Tuathaigh; Paula M Moran; Xuechu C Zhen; John L Waddington
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

3.  Societal Costs of Schizophrenia in Denmark: A Nationwide Matched Controlled Study of Patients and Spouses Before and After Initial Diagnosis.

Authors:  Lene Halling Hastrup; Erik Simonsen; Rikke Ibsen; Jacob Kjellberg; Poul Jennum
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

Review 4.  The Cost of Relapse in Schizophrenia.

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

5.  Social exclusion of people with severe mental illness in Switzerland: results from the Swiss Health Survey.

Authors:  D Richter; H Hoffmann
Journal:  Epidemiol Psychiatr Sci       Date:  2017-12-13       Impact factor: 6.892

6.  Dysfunction of Large-Scale Brain Networks in Schizophrenia: A Meta-analysis of Resting-State Functional Connectivity.

Authors:  Debo Dong; Yulin Wang; Xuebin Chang; Cheng Luo; Dezhong Yao
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

7.  Impaired introspective accuracy in schizophrenia: an independent predictor of functional outcomes.

Authors:  Juliet Silberstein; Philip D Harvey
Journal:  Cogn Neuropsychiatry       Date:  2018-11-26       Impact factor: 1.871

8.  The association between early-onset schizophrenia with employment, income, education, and cohabitation status: nationwide study with 35 years of follow-up.

Authors:  Christian Hakulinen; John J McGrath; Allan Timmerman; Niels Skipper; Preben Bo Mortensen; Carsten Bøcker Pedersen; Esben Agerbo
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-08-27       Impact factor: 4.328

Review 9.  The Societal Cost of Schizophrenia: A Systematic Review.

Authors:  Huajie Jin; Iris Mosweu
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

10.  Dopamine-Induced Dysconnectivity Between Salience Network and Auditory Cortex in Subjects With Psychotic-like Experiences: A Randomized Double-Blind Placebo-Controlled Study.

Authors:  Julian Rössler; Wulf Rössler; Erich Seifritz; Lui Unterrassner; Thomas Wyss; Helene Haker; Diana Wotruba
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.